TDM for Optimized Outcome in Patients With mRCC.
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNiels Fristrup
About this trial
The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy and side effects. It furthermore holds microbiome characterization of CPI-treated patients.
Furthermore, the investigators examines the role of anti-drug antibodies and receptor polymorphisms in CTLA-4 and PD-1 receptors in treatment failure among patients with mRCC treated with check point immunotherapy (CPI). Moreover, polymorphisms in the UGT1A1 gene will be correlated with the pazopanib treatment dose.
Eligibility criteria
Qualifiers
Patients in Denmark with medically treated metastatic renal cell carcinoma.
Disqualifiers
No written informed consent.
Trial design
Treatments tested in this trial
- Measurement of concentration of active metabolite in cancer treatment.
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Niels Fristrup
Lead sponsor
Aarhus University Hospital
Sponsor institution
Herlev Hospital
Collaborator
Rigshospitalet, Denmark
Collaborator
Source ClinicalTrials.gov